According to Zhitong Finance App News, Chengyi Pharmaceutical (603811.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 432 million yuan, an increase of 3.63%; net profit attributable to shareholders of listed companies was 94.87 million yuan, a year-on-year decrease of 15.61%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 92.45 million yuan, a year-on-year decrease of 16.83%; basic earnings per share were 0.21 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.